Genmab — November 2017
-
had to smile here, it reads "We thank AbbVie, Celgene, Takeda and Amgen for their support" and then the guy says: "Dara clearly is going to have a potential role in maintenance setting in the future " wrong sponsor mate
https://www.patientpower.info/video/ask-the-expert-any-updates-on-the-use-of-the-new-immuno-drugs-for-maintenance-in-myeloma -
meanwhile HollandBio promoting itself at BIO Europe with the cheapest box they could find
https://twitter.com/HollandBIO/status/927880167099392000 -
Genmab to Present at the Jefferies 2017 London Healthcare Conference
Media Release Copenhagen, Denmark; November 7, 2017 – Genmab A/S (Nasdaq Copenhagen: GEN) announced today that the company’s CEO, Jan van de Winkel,...
GlobeNewswire News Room (globenewswire.com)
-
Man kan altid håbe på noget bedre i morgen....på nær vejret, det klager vi ikke over...skål og godaften til alle hjemme i kolde DK -:)
-
-
GSK får BTD for deres BCMA-ADC GSK2857916. https://myelomaresearchnews.com/2017/11/06/multiple-myeloma-investigational-therapy-gsk2857916-gsk-breakthrough-therapy-designation-fda/
-
Pom-dex er mere omkostningseffektiv end dara mono og cafilzomib mono i RRMM. https://myelomaresearchnews.com/2017/10/30/myeloma-study-finds-pomalyst-more-cost-effective-than-kyprolis-or-darzalex/
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind